{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polycystic-ovary-syndrome/management/management-adults/","result":{"pageContext":{"chapter":{"id":"5c7d454c-e837-5db4-96b6-d7259cedcbb1","slug":"management-adults","fullItemName":"Scenario: Management - adults","depth":2,"htmlHeader":"<!-- begin field 3f55fdc1-689b-4e2b-a208-be9061afa8c3 --><h2>Scenario: Management of polycystic ovary syndrome in adults</h2><!-- end field 3f55fdc1-689b-4e2b-a208-be9061afa8c3 -->","summary":"Covers the management of polycystic ovary syndrome (PCOS) and associated disorders in adults.","htmlStringContent":"<!-- begin item 50c6c341-4985-4028-a7e7-4c5fadb0ee62 --><!-- begin field 6eaf6f4c-0a15-446d-a816-acbc0157fd6a --><p>From age 18 years onwards (Female).</p><!-- end field 6eaf6f4c-0a15-446d-a816-acbc0157fd6a --><!-- end item 50c6c341-4985-4028-a7e7-4c5fadb0ee62 -->","topic":{"id":"daaf23b6-59bf-5fa9-96d9-6d98f028d2bd","topicId":"90f70ae3-1caf-4e74-8397-cf2655cfb10c","topicName":"Polycystic ovary syndrome","slug":"polycystic-ovary-syndrome","lastRevised":"Last revised in September 2018","chapters":[{"id":"6f41b5a4-2e7e-5469-91c8-15331570cb8c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ad66803-f217-58c6-ad92-d9db6491cb26","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"132cf0f7-983a-59b8-aa99-10f350089b7c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d45a2f22-c9b6-5ee0-afb6-8ae3d0397d9f","slug":"changes","fullItemName":"Changes"},{"id":"e3852569-27c3-5e63-ab2f-2b92dcfe5262","slug":"update","fullItemName":"Update"}]},{"id":"f1fe2489-77fe-5403-977f-d3603e5bae1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"048d9ada-61af-59a9-971e-42aed733010a","slug":"goals","fullItemName":"Goals"},{"id":"845cd360-b1c4-50ee-a60f-5ec2ce05b2b8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6bed55f9-2ee7-578e-8770-b9a5e2053955","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0afb7a34-d84c-5ad9-bcc3-0dc5345cd2b8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7587b9f-e03a-5ba0-b6c5-173412097eb9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b7749edb-c354-5cb9-adc7-04cbe456d37d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"390c9f6a-9392-5672-8a5d-2945f5be467d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5ae79977-6f68-54e7-bae5-d3a83aa4bad7","slug":"definition","fullItemName":"Definition"},{"id":"86ec422e-1b3a-5c12-b4df-64886e831aea","slug":"causes","fullItemName":"Causes"},{"id":"87943c47-132e-5d7b-bba7-9f5fd8d2fdd8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fd9eddac-eb60-523a-9a51-e94719b6fef4","slug":"complications","fullItemName":"Complications"},{"id":"104e8e2a-4d4d-5fc6-b68f-5337dd3ccc87","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26e7fb06-0e4c-5c05-aea8-632061b95e52","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6f9e9e17-1a64-5142-813c-89d3dc869c6d","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"483e27e7-00c5-5c3a-b61b-d00edbcafdd7","slug":"investigations","fullItemName":"Investigations"},{"id":"6a10f0bc-d2b9-504d-beb4-a033a4cfb16b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"82ce27d1-1cdc-5a75-8d26-8bbb3d8d62d7","fullItemName":"Management","slug":"management","subChapters":[{"id":"5c7d454c-e837-5db4-96b6-d7259cedcbb1","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"762c879d-8353-5b98-98e3-cd5e9dd9238e","slug":"management-adolescents","fullItemName":"Scenario: Management - adolescents"}]},{"id":"980e12cc-a3a7-5006-9004-9a3817403978","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8c324c3d-d93a-5a1b-9a8f-070221373b1a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0096e783-16f8-5f5a-9660-d3685b777a10","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"af33ae46-9b14-5c06-98b3-689fc80c683f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"61bd6f68-6b5a-5980-aec9-07bcbf6dc232","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3d02f180-e5e5-5a10-a991-a415041c663f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17c9b913-2bf1-5468-a926-0f8643a69cc1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"696b4fff-16f7-5d8a-a5d1-da81a7a53ffc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"82ce27d1-1cdc-5a75-8d26-8bbb3d8d62d7","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"732ff771-29b2-50b9-8a82-4234bf2d9840","slug":"general-management","fullItemName":"General management","depth":3,"htmlHeader":"<!-- begin field 055305e2-3b38-44cd-b018-b34c60710c12 --><h3>How should I manage polycystic ovary syndrome in adults?</h3><!-- end field 055305e2-3b38-44cd-b018-b34c60710c12 -->","summary":null,"htmlStringContent":"<!-- begin item 6060b4e3-7607-423f-9063-30082a88a0a9 --><!-- begin field ef000e9e-a3fb-4920-ad46-21036045e2e5 --><ul><li><strong>Inform women diagnosed with polycystic ovary syndrome (PCOS) about the possible long-term <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">complications</a> of PCOS,</strong> including type 2 diabetes and cardiovascular disease (CVD).<ul><li>Encourage a healthy lifestyle to reduce the risk of these complications and to help improve the clinical features of PCOS, including oligomenorrhoea or amenorrhoea, acne, hirsutism, and infertility. </li><li>For women who are overweight or obese, offer advice on weight loss or consider referral to a dietitian. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li><li>Explain that weight loss may:<ul><li>Reduce hyperinsulinism and hyperandrogenism.</li><li>Reduce the risk of type 2 diabetes and CVD.</li><li>Result in menstrual regularity.</li><li>Improve the chance of pregnancy (if it is desired). </li></ul></li></ul></li><li><strong>Offer screening for:</strong><ul><li>Impaired glucose tolerance and type 2 diabetes. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/management/management-adults/#screening-for-type-2-diabetes-insulin-resistance\">Screening for type 2 diabetes and insulin resistance</a> for more information.</li><li>Cardiovascular risk factors. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/management/management-adults/#screening-for-cardiovascular-risk-factors\">Screening for cardiovascular risk factors</a> for more information.</li></ul></li><li><strong>Ask about snoring and daytime fatigue/somnolence.</strong><ul><li>If there are symptoms of obstructive sleep apnoea, refer for investigation and treatment.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a> for more information.</li></ul></li><li><strong>Ask about emotional well being, and manage as appropriate.</strong><ul><li>Screen for depression and anxiety, where appropriate. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> for more information.</li><li>Consider the possibility of the following:<ul><li>Psychosexual problems — hirsutism, obesity, oligomenorrhoea, and infertility may lead to feelings of being unattractive, and loss of feminine identity.</li><li>Negative body image — women with PCOS may feel less physically attractive, physically fit or healthy and may be less satisfied with their body size than women without PCOS.</li><li>Eating disorders — these include anorexia nervosa, bulimia nervosa, binge-eating disorder, and atypical eating disorders. See the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/eating-disorders/\">Eating disorders</a>.</li></ul></li></ul></li><li><strong>Manage <strong>the clinical features</strong> <strong>of PCOS</strong>, including </strong>oligomenorrhoea or amenorrhoea, acne, hirsutism, and infertility. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/management/management-adults/#managing-clinical-features-of-polycystic-ovary-syndrome\">Managing clinical features of polycystic ovary syndrome</a> for more information.</li><li><strong>For women with PCOS who are pregnant or considering pregnancy:</strong><ul><li>Consider referring the woman to be screened for gestational diabetes. <ul><li>All women who are planning a pregnancy should be offered a 75-g oral glucose tolerance test (OGTT). If this is not performed preconception, it should be offered before 20 weeks gestation.</li><li>All pregnant women with PCOS should be offered an OGTT at 24–28 weeks gestation. </li></ul></li><li>Consider whether any changes to drug treatment(s) should be made. For example, <ul><li>Metformin is not recommended in pregnancy. Seek specialist advice.</li><li>Any hormonal treatment (such as medroxyprogesterone for inducing cyclical bleeding) should be stopped.</li></ul></li></ul></li><li><strong>Provide sources of additional information and support. </strong>For example:<ul><li>Information on PCOS are available from:<ul><li>The Royal College of Obstetricians and Gynaecologists (RCOG) website (www.rcog.org.uk): <a data-hyperlink-id=\"4c54ce56-014b-4b6f-854f-a95f00cb5582\" href=\"https://www.rcog.org.uk/globalassets/documents/patients/patient-information-leaflets/gynaecology/pi-pcos.pdf\">Polycystic ovary syndrome: what it means for your long-term health</a>.</li><li>NHS (www.nhs.uk): <a data-hyperlink-id=\"4c363da2-b2bd-4693-abdc-a95f00cb55d8\" href=\"https://www.nhs.uk/conditions/polycystic-ovary-syndrome-pcos/\">Polycystic ovary syndrome</a>.</li></ul></li><li>Support groups for people with PCOS include:<ul><li>PCOS Challenge: The National Polycystic Ovary Syndrome Association (<a data-hyperlink-id=\"52cac0f3-2b9d-42d9-9b67-a96700c58c1f\" href=\"https://www.pcoschallenge.org/about-pcos-challenge/\">www.pcoschallenge.org</a>).</li><li>Verity (<a data-hyperlink-id=\"e7448387-1932-4df7-ab2c-a96700c58c95\" href=\"https://www.verity-pcos.org.uk/about-us.html\">www.verity-pcos.org.uk</a>).</li></ul></li></ul></li></ul><!-- end field ef000e9e-a3fb-4920-ad46-21036045e2e5 --><!-- end item 6060b4e3-7607-423f-9063-30082a88a0a9 -->","subChapters":[{"id":"23cd4895-035c-5bfb-9899-e9615dae7399","slug":"basis-for-recommendation-498","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e8ebeca4-1714-4b17-942b-a95e00e0761f --><h4>Basis for recommendation</h4><!-- end field e8ebeca4-1714-4b17-942b-a95e00e0761f -->","summary":null,"htmlStringContent":"<!-- begin item 498cb71c-edc0-4127-a0e6-a95e00e075ea --><!-- begin field cd638223-546b-46cb-b86b-a95e00e0761f --><p>These recommendations are based largely on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>], <em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>], and the<em> I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued by the International Polycystic Ovary Syndrome (PCOS) Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</p><h5>Encouraging a healthy lifestyle</h5><ul><li>The ESE advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>]:<ul><li>Lifestyle modification, including diet and exercise, should be the first-line treatment in overweight and obese women with PCOS.</li><li>Regular exercise combined with dietary advice aiming at sustained weight loss may ameliorate many aspects of PCOS in overweight/obese women.<ul><li>For example, weight reduction alone may result in spontaneous ovulation in these women, and in women who do not ovulate spontaneously following weight reduction and lifestyle modifications, the response to induction of ovulation is likely to be improved by these measures. </li></ul></li></ul></li><li>The International PCOS Network advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Healthy lifestyle behaviours (including healthy eating and regular physical activity) should be recommended in all those with PCOS to achieve and/or maintain a healthy weight and to optimize hormonal outcomes, general health, and quality of life.</li><li>Lifestyle intervention (preferably multicomponent, including diet, exercise, and behavioural strategies) should be recommended in all those with PCOS and excess weight, for reductions in weight, central obesity, and insulin resistance.</li></ul></li><li>Expert opinion in a British Fertility Society Policy and Practice Guidelines is that a loss of more than 5% in body weight can be enough to restore fertility and improve metabolic markers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Balen and Anderson, 2007</a>].</li></ul><h5>Offering screening for impaired glucose tolerance and type 2 diabetes</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/management/management-adults/#screening-for-type-2-diabetes-insulin-resistance\">Screening for type 2 diabetes and insulin resistance</a> for more information.</li></ul><h5>Offering screening for cardiovascular risk factors</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/management/management-adults/#screening-for-cardiovascular-risk-factors\">Screening for cardiovascular risk factors</a> for more information.</li></ul><h5>Asking about snoring and daytime fatigue/somnolence</h5><ul><li>The prevalence of obstructive sleep apnoea is increased in obese women with PCOS. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>The International PCOS Network advises that screening for obstructive sleep apnoea should be considered to identify and alleviate related symptoms, such as snoring, waking unrefreshed from sleep, daytime sleepiness, and the potential for fatigue to contribute to mood disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><h5>Asking about emotional well being</h5><ul><li>Women with PCOS are at increased risk of psychological and behavioural disorders as well as reduced quality of life. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>The International PCOS Network advises that health professionals should be aware of the increased prevalence of psychosexual dysfunction and should consider exploring how features of PCOS, including hirsutism and body image, impact on sex life and relationships in PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><h5>Managing the clinical features of PCOS</h5><ul><li><p>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/management/management-adults/#managing-clinical-features-of-polycystic-ovary-syndrome\">Managing clinical features of polycystic ovary syndrome</a> for more information.</p></li></ul><h5>Managing women with PCOS who are pregnant or considering pregnancy</h5><ul><li>Women with PCOS have a clinically significant increased risk of pregnancy complications compared with women without PCOS. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>The information on when and how an oral glucose tolerance test should be done is based on expert opinion in the RCOG guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>] and the <em>International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li><li>The recommendation to consider whether any changes to drug treatment should be made is based on what CKS considers to be good clinical practice.</li></ul><h5>Providing sources of additional information and support</h5><ul><li>Providing sources of additional information and support is based on expert opinion in the <em>International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><!-- end field cd638223-546b-46cb-b86b-a95e00e0761f --><!-- end item 498cb71c-edc0-4127-a0e6-a95e00e075ea -->","subChapters":[]}]},{"id":"2f144f62-2ba5-5f15-b77e-c137553a79c2","slug":"screening-for-type-2-diabetes-insulin-resistance","fullItemName":"Screening for type 2 diabetes and insulin resistance","depth":3,"htmlHeader":"<!-- begin field cbd6477d-cfda-40e1-a5e2-f676ebdf2d21 --><h3>How should I screen for type 2 diabetes and insulin resistance?</h3><!-- end field cbd6477d-cfda-40e1-a5e2-f676ebdf2d21 -->","summary":null,"htmlStringContent":"<!-- begin item 78b8747d-dcbd-4fe9-aa9e-f2acc1db101b --><!-- begin field e8b7970a-91f1-41da-bb4f-b765410fe191 --><ul><li><strong>Offer a</strong><strong> 2-hour post 75 g oral glucose tolerance test (OGTT) to women with polycystic ovary syndrome (PCOS) who are:</strong><ul><li>Overweight (body mass index [BMI] 25 kg/m<sup>2</sup> or more).</li><li>Not overweight (BMI less than 25 kg/m<sup>2</sup> ) but have additional risk factors, such as advanced age (older than 40 years of age), personal history of gestational diabetes, or family history of type 2 diabetes.</li><li>Of non-Caucasian ethnicity (particularly south Asian women) regardless of their BMI, because of their propensity towards higher insulin resistance.</li></ul></li><li><strong>Offer an annual OGTT to women with:</strong><ul><li>Impaired fasting glucose (fasting plasma glucose level from 6.1 mmol/l to 6.9 mmol/l), <em>or </em></li><li>Impaired glucose tolerance (plasma glucose of 7.8 mmol/l or more but less than 11.1 mmol/l after a 2-hour OGTT).</li></ul></li><li><strong>Do not initiate treatment with insulin-sensitizing drugs, such as metformin, in primary care.</strong> Refer to a specialist if this is being considered.<ul><li>There is no consensus on who should be referred for consideration of insulin-sensitizing drugs. Consider referring women with:<ul><li>Severe oligomenorrhoea or amenorrhoea.</li><li>Impaired glucose tolerance or impaired fasting glucose.</li><li>Low sex hormone-binding globulin levels (as this is a surrogate marker for insulin resistance).</li></ul></li></ul></li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for information on how to manage type 2 diabetes.</li></ul><!-- end field e8b7970a-91f1-41da-bb4f-b765410fe191 --><!-- end item 78b8747d-dcbd-4fe9-aa9e-f2acc1db101b -->","subChapters":[{"id":"c6c254b1-64e5-5499-b210-1f7ef678655b","slug":"basis-for-recommendation-3e2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4d9feb7a-4218-4ef6-a589-99832deccde6 --><h4>Basis for recommendation</h4><!-- end field 4d9feb7a-4218-4ef6-a589-99832deccde6 -->","summary":null,"htmlStringContent":"<!-- begin item 3e2b6f56-7f06-455f-bcfc-dcfe16eb2b25 --><!-- begin field f97874c0-5528-4dd9-b8f4-c2197e1a26a6 --><p>These recommendations are based on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>], <em>Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society</em>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Wild et al, 2010</a>], <em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>], and the<em> I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued by the International PCOS Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</p><h5>Offering an oral glucose tolerance test (OGTT)</h5><ul><li>Women with PCOS have an increased risk of impaired glucose tolerance and type 2 diabetes. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.<ul><li>The International PCOS Network advises that glycaemic status should be assessed at baseline in all women with PCOS. Thereafter, assessment should be every 1–3 years, depending on the presence of other diabetes risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li><li>The RCOG advises that an annual OGTT should be performed in women with impaired fasting glucose (fasting plasma glucose level from 6.1 mmol/l to 6.9 mmol/l) or impaired glucose tolerance (plasma glucose of 7.8 mmol/l or more but less than 11.1 mmol/l after a 2-hour OGTT) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]</li><li>The AE-PCOS Society advises that an OGTT should be performed in all obese women with PCOS, in lean PCOS women with advanced age (older than 40 years), and in the presence of a personal history of gestational diabetes or a family history of type 2 diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Wild et al, 2010</a>].</li></ul></li><li>An OGTT is considered to be appropriate for screening women with PCOS for diabetes. <ul><li>According to the RCOG, fasting blood glucose level alone has been shown to be inaccurate and results in underdiagnosis of type 2 diabetes in women with PCOS, and the use of HbA1c for the diagnosis of diabetes in PCOS needs better definition. However, if the woman is unwilling to have an OGTT or where the resources are not readily available, it would be reasonable to carry out HbA1c measurements  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>].</li><li>The ESE guideline states that fasting plasma glucose and HbA1c are not sensitive methods of screening for type 2 diabetes in situations of risk, such as PCOS, although as a screening tool with adjusted criteria, fasting glucose may have some use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>].</li><li>The International PCOS Network recommends that an OGTT, fasting plasma glucose, or HbA1c may be performed to assess glycaemic status. However, in high-risk women with PCOS (including a women with a body mass index [BMI] greater than 25 kg/m<sup>2</sup> or in Asians greater than 23 kg/m<sup>2</sup> , history of impaired fasting glucose, impaired glucose tolerance or gestational diabetes, family history of type 2 diabetes, hypertension, or high-risk ethnicity), an OGTT is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul></li></ul><h5>Insulin-sensitizing drugs</h5><ul><li>The RCOG makes the following points about the use of insulin-sensitizing drugs, such as metformin and the thiazolidinediones, in women with PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]:<ul><li>There is no evidence of long-term benefit.</li><li>Evidence suggests that metformin may have short-term effects on insulin resistance in women without diabetes.</li><li>Metformin may reduce androgen levels by about 11% in women with PCOS compared with placebo.</li><li>Evidence regarding metformin and reduction in body weight is conflicting.</li><li>Women with a BMI greater than 37 kg/m<sup>2 </sup>may not respond well to the standard dose of metformin.</li><li>There is no current robust evidence to support the use of these drugs for the prevention of cardiovascular disease in PCOS.</li><li>Evidence suggests that metformin is no better than diet and lifestyle at improving metabolic risk and progression to type 2 diabetes.</li><li>Metformin and the thiazolidinediones are unlicensed for use in PCOS.</li></ul></li><li>Due to the uncertainty about the benefits and safety of insulin-sensitizing drugs in PCOS, CKS recommends that they be initiated by a specialist.</li><li>There is no expert consensus on which women should be referred for treatment with an insulin-sensitizing drug.<ul><li>The RCOG recommends that metformin can be considered in women with PCOS who are already undergoing lifestyle treatment and do not have improvement in impaired glucose tolerance and in women with impaired glucose tolerance. </li><li>Previous expert reviewers of this CKS topic recommend referring women with:<ul><li>Severe oligomenorrhoea or amenorrhoea.</li><li>Impaired glucose tolerance or impaired fasting glucose.</li><li>Low sex hormone-binding globulin levels (as this is a surrogate marker for insulin resistance).</li></ul></li></ul></li></ul><!-- end field f97874c0-5528-4dd9-b8f4-c2197e1a26a6 --><!-- end item 3e2b6f56-7f06-455f-bcfc-dcfe16eb2b25 -->","subChapters":[]}]},{"id":"be7191e6-6a47-52fc-ae50-937cc4865c10","slug":"screening-for-cardiovascular-risk-factors","fullItemName":"Screening for cardiovascular risk factors","depth":3,"htmlHeader":"<!-- begin field 9f662205-822a-454f-8ae7-1f0eabbdb58e --><h3>How should I assess for cardiovascular risk factors?</h3><!-- end field 9f662205-822a-454f-8ae7-1f0eabbdb58e -->","summary":null,"htmlStringContent":"<!-- begin item a6ad3721-6ec7-4d68-975d-d3e1e5d62139 --><!-- begin field 5e3785f6-fe1c-4a5b-a812-6397a6f917fc --><ul><li><strong>Assess individual cardiovascular disease (CVD) risk factors,</strong> including waist circumference, body mass index (BMI), level of physical activity, cigarette smoking, lipid levels, blood pressure, impaired glucose tolerance, and type 2 diabetes (personal and family history).<ul><li>Advise on measures to reduce cardiovascular risk, including diet, exercise, and where appropriate, weight loss and smoking cessation. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> and <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li><li>Check blood pressure, and manage women with hypertension. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a> for more information.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/management/management-adults/#screening-for-type-2-diabetes-insulin-resistance\">Screen</a> for type 2 diabetes and insulin resistance, and manage appropriately. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for information on managing women with type 2 diabetes.</li><li>Check lipid levels. See the section on <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/#interventions-tests-before-drug-treatment\">Lipid measurement</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a> for more information. Refer to a specialist if dyslipidaemia requires treatment.</li></ul></li><li><strong>If appropriate, calculate the woman's </strong><strong>10 year CVD risk using the QRISK<sup>®</sup>2 assessment tool, and manage appropriately.</strong> See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information. Note that:<ul><li>Conventional cardiovascular risk calculators have not been validated in women with polycystic ovary syndrome.</li><li>The QRISK<sup>®</sup>2 assessment tool is not suitable for:<ul><li>People who already have CVD. </li><li>People with type 1 diabetes. </li><li>People with chronic kidney disease (estimated glomerular filtration rate [eGFR] less than 60 mL/min/1.73 m<sup>2</sup> and/or albuminuria [a urinary albumin:creatinine ratio greater than 3 mg/mmol]). </li><li>People with familial hypercholesterolaemia. </li><li>People aged 85 years or older. </li></ul></li></ul></li><li><strong>Offer all women with polycystic ovary syndrome (PCOS):</strong><ul><li>Regular monitoring for weight change and excess weight. Monitoring could be at each visit or at a minimum 6–12 monthly, with frequency, planned and agreed with the woman.</li><li>Annual blood pressure checks (or more frequently based on global CVD risk).</li></ul></li></ul><!-- end field 5e3785f6-fe1c-4a5b-a812-6397a6f917fc --><!-- end item a6ad3721-6ec7-4d68-975d-d3e1e5d62139 -->","subChapters":[{"id":"5d19ff19-899f-586b-9181-924d04695e30","slug":"basis-for-recommendation-d22","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field aff4b155-2609-412d-b025-3cd5d53c9ca2 --><h4>Basis for recommendation</h4><!-- end field aff4b155-2609-412d-b025-3cd5d53c9ca2 -->","summary":null,"htmlStringContent":"<!-- begin item d22a06bd-48e7-41cb-ae42-245b23a2cc14 --><!-- begin field 382d8a96-77bd-4e66-bdd4-6eec087b7775 --><p>These recommendations are based largely on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>], <em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>], and the<em> I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued by the International Polycystic Ovary Syndrome<em> </em>(PCOS) Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</p><h5>Assessing for (and managing) cardiovascular disease (CVD) risk</h5><ul><li>There is some evidence that CVD risk factors are increased in PCOS. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>CKS recommends that, in view of the possible increased risk of cardiovascular events, clinicians should give advice on measures to reduce cardiovascular risk.</li><li>The RCOG recommends that because the lifetime risk for CVD is higher in women with PCOS, and is mostly preventable, all women with PCOS should be assessed for CVD risk by assessing individual CVD risk factors at baseline and managed accordingly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]. </li><li>The International PCOS Network advises that women with PCOS should be assessed for cardiovascular risk factors and global CVD risk. If screening reveals CVD risk factors, including obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, and lack of physical activity, the woman should be considered at increased risk of CVD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><h5>Referral if dyslipidaemia requires treatment</h5><ul><li>Although there is some evidence that statins improve hyperandrogenaemia and the metabolic profile in women with PCOS, they are not licensed for these indications. The RCOG advises that lipid-lowering treatment is not recommended routinely in women with PCOS and should only be prescribed by a specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]. </li></ul><h5>Calculating cardiovascular risk score using the QRISK<sup>®</sup>2 tool</h5><ul><li>The QRISK<sup>®</sup>2 tool calculates a person's estimated risk (not lifetime risk) of CVD over a 10 year period. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li><li>The RCOG warns that while it seems prudent to assess the cardiovascular risk factors of a woman with PCOS, it should be noted that the conventional cardiovascular risk calculators have not been validated in this group of women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]. </li></ul><h5>Offering all women with PCOS regular weight monitoring and annual blood pressure checks</h5><ul><li>This recommendation is based on expert opinion in the <em>I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018 </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><!-- end field 382d8a96-77bd-4e66-bdd4-6eec087b7775 --><!-- end item d22a06bd-48e7-41cb-ae42-245b23a2cc14 -->","subChapters":[]}]},{"id":"74b53af4-8301-5664-ab51-a38c0864e3ca","slug":"managing-clinical-features-of-polycystic-ovary-syndrome","fullItemName":"Managing clinical features of polycystic ovary syndrome","depth":3,"htmlHeader":"<!-- begin field 783c0ee7-ef4f-4fa9-b83c-c398d57b7c75 --><h3>How should I manage clinical features of polycystic ovary syndrome?</h3><!-- end field 783c0ee7-ef4f-4fa9-b83c-c398d57b7c75 -->","summary":null,"htmlStringContent":"<!-- begin item 0278eca8-3034-4e08-8975-4d6f213be4d9 --><!-- begin field 366400ec-e2fb-489f-8dfb-59e5b1c4f293 --><ul><li><strong>Oligomenorrhoea or amenorrhoea</strong><ul><li>If the woman has prolonged amenorrhea (less than one period every three months), abnormal vaginal bleeding, or excess weight:<ul><li>Prescribe a cyclical progestogen (such as medroxyprogesterone 10 mg daily for 14 days) to induce a withdrawal bleed, <em>then </em></li><li>Refer for a transvaginal ultrasound to assess endometrial thickness.</li></ul></li><li>If endometrial thickening is present (greater than 10 mm) or the endometrium has an unusual appearance:<ul><li>Refer for endometrial sampling to exclude endometrial hyperplasia or cancer.</li></ul></li><li>If the endometrium is of normal thickness and appearance, advise treatment to prevent endometrial hyperplasia. The choice of treatment depends on factors such as whether the woman wishes to have regular withdrawal bleeds (at least every 3–4 months), whether she has acne or hirsutism, and whether there are any contraindications to treatment. Options include:<ul><li>A cyclical progestogen, such as medroxyprogesterone 10 mg daily for 14 days every 1–3 months.</li><li>A low-dose combined oral contraceptive (COC). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for prescribing information on COCs, including contraindications and cautions, choice, risks and adverse effects, and drug interactions.</li><li>The levonorgestrel-releasing intrauterine system (LNG-IUS). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/\">Contraception - IUS/IUD</a> for prescribing information on the LNG-IUS, including contraindications, cautions, risks, and adverse effects.</li></ul></li><li>If the woman is unwilling to take cyclical hormone treatment or use the LNG-IUS, seek specialist advice or refer. Regular ultrasonography is likely to be required (for example every 6–12 months) to assess endometrial thickness and morphology.</li><li>Encourage a healthy lifestyle to reduce the risk of possible long-term <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">complications</a> of polycystic ovary syndrome (PCOS).  <ul><li>Advise women who are overweight or obese that weight loss may result in menstrual regularity. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li>Osteoporosis prophylaxis is <em>not</em> required for women with PCOS who are amenorrhoeic, as they are not oestrogen deficient.</li></ul></li><li><strong>Acne</strong><ul><li>Encourage a healthy lifestyle to reduce the risk of possible long-term <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">complications</a> of PCOS. <ul><li>Advise women who are overweight or obese that weight loss may reduce hyperandrogenism. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li>Offer a COC as a first-line treatment, provided there are no contraindications. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for prescribing information on COCs, including contraindications and cautions, choice, risks and adverse effects, and drug interactions.</li><li>If needed, add a topical retoinoids, topical antibiotics, and/or oral antibiotics. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/acne-vulgaris/\">Acne vulgaris</a> for more information on managing acne.</li></ul></li><li><strong>Hirsutism</strong><ul><li>Encourage a healthy lifestyle to reduce the risk of possible long-term <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">complications</a> of PCOS. <ul><li>Advise women who are overweight or obese that weight loss may reduce hyperandrogenism. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li>Discuss methods of hair reduction and removal (such as shaving and waxing), as these will remain an important part of management. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hirsutism/\">Hirsutism</a> for more information.</li><li>Consider prescribing a COC, provided there are no contraindications. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for prescribing information on COCs, including contraindications and cautions, choice, risks and adverse effects, and drug interactions.</li></ul></li><li><strong>Infertility</strong><ul><li>Carry out an assessment to identify the possible causes of infertility, which might not be due to PCOS. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/infertility/\">Infertility</a> for more information.</li><li>Encourage a healthy lifestyle to reduce the risk of possible long-term <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">complications</a> of PCOS. <ul><li>Advise women who are overweight or obese that weight loss may improve the chance of pregnancy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li><li>Advise women who smoke that smoking is likely to reduce their fertility and that passive smoking is likely to reduce their chances of conceiving. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li></ul></li><li>Consider referral for fertility treatment. </li></ul></li></ul><!-- end field 366400ec-e2fb-489f-8dfb-59e5b1c4f293 --><!-- end item 0278eca8-3034-4e08-8975-4d6f213be4d9 -->","subChapters":[{"id":"30aa418c-4b65-5051-b501-c059610f9d8a","slug":"basis-for-recommendation-7db","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 83138d5d-2217-43c1-a6c7-754efe5862f9 --><h4>Basis for recommendation</h4><!-- end field 83138d5d-2217-43c1-a6c7-754efe5862f9 -->","summary":null,"htmlStringContent":"<!-- begin item 7db916bd-f6eb-4a6c-9007-5f414e6bbdbe --><!-- begin field 0686eb41-2371-43d3-a231-7aee0d7d4124 --><p>These recommendations are based largely on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>], <em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>], and the<em> I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued by the International Polycystic Ovary Syndrome<em> </em>(PCOS) Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]. </p><h5>Inducing a withdrawal bleed</h5><ul><li>In women with PCOS, intervals between menstruation of more than 3 months (equivalent to fewer than four periods each year) may predispose to endometrial hyperplasia and later carcinoma. The RCOG states that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]:<ul><li>It is good clinical practice to induce a withdrawal bleed at least every 3–4 months to reduce this risk. This can be done with a cyclical progestogens for at least 12 days, a combined oral contraceptive pill (COC), or a levonorgestrel-releasing intrauterine system. There is no evidence to suggest which is the most effective regimen.<ul><li>Medroxyprogesterone is indicated for endometrial protection from oestrogenic hormone replacement therapy as a 14-day course within each 28-day oestrogen hormone replacement therapy cycle [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">BNF 76, 2018</a>].</li></ul></li><li>Transvaginal ultrasound should be considered in the absence of withdrawal bleeds or abnormal uterine bleeding.</li><li>A thickened endometrium or an endometrial polyp should prompt consideration of endometrial biopsy and/or hysteroscopy (in PCOS, an endometrial thickness of less than 7 mm is unlikely to be hyperplasia).</li></ul></li><li>According to the International PCOS Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Routine ultrasound screening of endometrial thickness in PCOS is not recommended. However, health professionals require a low threshold for investigation of endometrial cancer in women with PCOS or a history of PCOS.</li><li>Investigation by transvaginal ultrasound and/or endometrial biopsy is recommended if there is persistent thickened endometrium and/or risk factors such as prolonged amenorrhea, abnormal vaginal bleeding, or excess weight.</li></ul></li></ul><h5>Managing women who are unwilling to take cyclical hormone treatment</h5><ul><li>These recommendations are based on expert opinion in a non-systematic review on PCOS and cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Balen, 2001</a>].</li></ul><h5>Encouraging a healthy lifestyle</h5><ul><li>The ESE advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>]:<ul><li>Lifestyle modification, including diet and exercise, should be the first-line treatment in overweight and obese women with PCOS.</li><li>Regular exercise combined with dietary advice aiming at sustained weight loss may ameliorate many aspects of PCOS in overweight/obese women.<ul><li>For example, weight reduction alone may result in spontaneous ovulation in these women, and in women who do not ovulate spontaneously following weight reduction and lifestyle modifications, the response to induction of ovulation is likely to be improved by these measures. </li></ul></li></ul></li><li>The International PCOS Network advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Healthy lifestyle behaviours (including healthy eating and regular physical activity) should be recommended in all those with PCOS to achieve and/or maintain a healthy weight and to optimize hormonal outcomes, general health, and quality of life.</li><li>Lifestyle intervention (preferably multicomponent, including diet, exercise, and behavioural strategies) should be recommended in all those with PCOS and excess weight, for reductions in weight, central obesity, and insulin resistance.</li></ul></li><li>Expert opinion in a British Fertility Society Policy and Practice Guidelines is that a loss of more than 5% in body weight can be enough to restore fertility and improve metabolic markers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Balen and Anderson, 2007</a>].</li></ul><h5>Choice of treatment </h5><ul><li>COCs are the mainstay of the pharmacological treatment of PCOS as they can be used to manage both menstrual disorders and androgen excess symptoms (such as acne and hirsutism). Progestogens, usually given cyclically, also have a role in the management of menstrual dysfunction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>].</li><li>The International PCOS Network advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Provided there are no contraindications, the COC alone should be recommended in adult women with PCOS for management of hyperandrogenism and/or irregular menstrual cycles.</li><li>When deciding on a treatment, the woman’s personal characteristics, preferences, and values should be considered as well as the benefits, adverse effects, and contraindications of the treatment.</li><li>The lowest effective oestrogen doses (such as 20–30 micrograms of ethinyloestradiol or equivalent) and natural estrogen preparations should be considered whilst balancing efficacy, metabolic risk profile, adverse effects, cost, and availability.</li><li>The generally limited evidence on the effects of COCs in PCOS should be considered, with practice informed by general population guidelines.</li><li>PCOS specific risk factors, such as high body mass index, hyperlipidemia, and hypertension, need to be considered.</li></ul></li></ul><h5>Osteoporosis prophylaxis not required for women who are amenorrhoeic</h5><ul><li>This recommendation is based on evidence from case-controlled studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Adami et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">To and Wong, 2005</a>] and on expert opinion in review articles on amenorrhoea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Crosignani and Vegetti, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Baird, 1997</a>].<ul><li>Women with PCOS have some ovarian activity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Crosignani and Vegetti, 1996</a>]. Follicular development and oestrogen production continue but are arrested at some stage short of full maturation of an ovulatory follicle. Therefore, although these women are anovulatory, they do not show signs of oestrogen deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Baird, 1997</a>].<ul><li>A small case-controlled study of 45 adolescent women with amenorrhoea or oligomenorrhoea (14 had polycystic ovaries) matched with 45 women with regular menstruation found that, although overall the women with amenorrhoea or oligomenorrhoea had lower bone mineral density than those with regular menstruation, those with polycystic ovaries had a bone mineral density similar to that of the control group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">To and Wong, 2005</a>].</li><li>A subgroup of 51 women with PCOS in a case-controlled study found that amenorrhoeic women with PCOS had only a marginal decrease in bone mass. Bone protection was thought to be due to adequate oestrogen production and overproduction of androgenic steroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Adami et al, 1998</a>].</li></ul></li></ul></li></ul><!-- end field 0686eb41-2371-43d3-a231-7aee0d7d4124 --><!-- end item 7db916bd-f6eb-4a6c-9007-5f414e6bbdbe -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}